Evidence map›Paper›PMID 42300746›Full record

ArticleChemical communications (Cambridge, England)2026

Bioorthogonal tuning of nanosurface opsonisation

Sarah Jacques, Hanmant Gaikwad, Jemma Pillatzke, Seyed Moein Moghimi, Dmitri Simberg

Abstract read
In one paragraph

Article in Chemical communications (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah JacquesDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. seyed.moghimi@newcastle.ac.uk.
Hanmant GaikwadDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. seyed.moghimi@newcastle.ac.uk.
Jemma PillatzkeSchool of Pharmacy and Pharmaceutical Sciences, Panoz Institute, Trinity College Dublin, Dublin 2, Ireland.
Seyed Moein MoghimiDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. seyed.moghimi@newcastle.ac.uk.ORCID http://orcid.org/0000-0003-0836-926X
Dmitri SimbergDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. seyed.moghimi@newcastle.ac.uk.

Funding

The Alternative Complement Pathway and Hemocompatibility of NanosurfacesR01AI154959 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Dmitri Simberg · 2020 to 2026
$3.5M
NIAID NIH HHS R01 AI154959
6 · The paper itself

Abstract

Complement opsonisation contributes to immune clearance of nanopharmaceuticals, but complement activation has some undesirable effects. Herein, we show that tethering the fusion complement receptor 2-complement receptor 1 (CR2-CR1) regulator to cross-linked iron oxide nanoworms

Indexed as

Complement System ProteinsNanoparticlesReceptors, Complement 3dRecombinant Fusion ProteinsClick ChemistryComplement ActivationHumansPolyethylene GlycolsComplement System ProteinsPolyethylene GlycolsReceptors, Complement 3dRecombinant Fusion Proteins

Identifiers

PMID42300746
PMCPMC13262778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.